Ingrid Fleming Selected Research

11,12-epoxy-5,8,14-eicosatrienoic acid

1/2012	11,12-EET stimulates the association of BK channel α and β(1) subunits in mitochondria to induce pulmonary vasoconstriction.
2/2011	Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels.
12/2008	Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response.
12/2005	Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ingrid Fleming Research Topics

Disease

19	Inflammation (Inflammations) 01/2022 - 09/2007
16	Hypoxia (Hypoxemia) 10/2020 - 11/2002
12	Neoplasms (Cancer) 01/2022 - 07/2011
12	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 04/2005
10	Atherosclerosis 01/2021 - 11/2004
8	Hypertension (High Blood Pressure) 01/2022 - 03/2003
7	Vascular Diseases (Vascular Disease) 01/2021 - 01/2008
6	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2013
6	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2008
6	Myocardial Infarction 01/2021 - 02/2011
5	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2013
4	Coronary Artery Disease (Coronary Atherosclerosis) 12/2018 - 02/2003
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 02/2003
4	Insulin Resistance 01/2016 - 01/2006
4	Diabetes Mellitus 07/2015 - 09/2008
4	Thrombosis (Thrombus) 01/2013 - 06/2007
4	Vascular Remodeling 03/2011 - 04/2006
4	Pulmonary Hypertension 02/2011 - 04/2006
3	Obesity 01/2022 - 07/2012
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2020 - 12/2017
3	Atherosclerotic Plaque (Atheroma) 06/2019 - 01/2013
3	Infarction (Infarctions) 01/2019 - 02/2011
2	Malignant Hyperthermia 01/2022 - 01/2020
2	Carcinoma (Carcinomatosis) 01/2022 - 01/2019
2	Body Weight (Weight, Body) 01/2022 - 09/2008
2	Polycystic Kidney Diseases (Polycystic Kidney Disease) 10/2021 - 01/2020
2	Carcinogenesis 07/2021 - 01/2021
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 10/2014
2	Disease Progression 01/2019 - 01/2018
2	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 01/2019 - 08/2015
2	Pathologic Neovascularization 01/2018 - 12/2011
2	Glioma (Gliomas) 09/2017 - 01/2016
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 08/2013 - 12/2005
2	Wounds and Injuries (Trauma) 06/2013 - 12/2011

Drug/Important Bio-Agent (IBA)

17	Proteins (Proteins, Gene)FDA Link 07/2021 - 12/2005
16	Epoxide HydrolasesIBA 07/2021 - 04/2005
15	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 07/2021 - 01/2004
14	EnzymesIBA 01/2022 - 01/2004
10	AcidsIBA 07/2021 - 01/2004
7	LipidsIBA 01/2022 - 01/2008
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 01/2004
6	CalpainIBA 12/2020 - 05/2009
6	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 07/2009
5	Retinaldehyde (Retinal)IBA 10/2021 - 03/2008
5	Epoxy Compounds (Epoxides)IBA 07/2021 - 10/2011
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2013
4	ProstaglandinsIBA 01/2022 - 07/2011
4	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022 - 12/2019
4	Messenger RNA (mRNA)IBA 02/2021 - 12/2005
4	Arachidonic Acid (Vitamin F)IBA 01/2021 - 01/2007
4	CytochromesIBA 01/2020 - 02/2011
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2019 - 04/2005
4	Angiotensin IIIBA 07/2013 - 11/2004
4	11,12-epoxy-5,8,14-eicosatrienoic acidIBA 01/2012 - 12/2005
3	CytokinesIBA 01/2022 - 12/2011
3	Insulin (Novolin)FDA Link 01/2022 - 04/2009
3	IntegrinsIBA 01/2021 - 09/2010
3	Docosahexaenoic AcidsIBA 01/2020 - 01/2019
3	CystathionineIBA 01/2020 - 01/2019
3	Biological ProductsIBA 01/2020 - 05/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 12/2011
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 12/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 02/2003
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 09/2008
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2016
3	MicroRNAs (MicroRNA)IBA 01/2018 - 07/2015
3	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2016 - 03/2003
3	Nitric Oxide Synthase (NO Synthase)IBA 01/2012 - 01/2008
3	Sulfaphenazole FDA Link 03/2008 - 01/2004
2	Cysteine (L-Cysteine)FDA Link 01/2022 - 01/2012
2	Naproxen (Naprosyn)FDA LinkGeneric 01/2022 - 06/2007
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2022 - 01/2020
2	Prostaglandin-E SynthasesIBA 01/2022 - 07/2011
2	Pyruvic Acid (Pyruvate)IBA 01/2022 - 01/2019
2	Dinoprostone (PGE2)FDA Link 01/2022 - 01/2020
2	ZymosanIBA 02/2021 - 10/2011
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2019
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2021 - 01/2012
2	EicosanoidsIBA 01/2020 - 01/2018
2	LyasesIBA 01/2020 - 01/2019
2	Tyrosine (L-Tyrosine)FDA Link 12/2019 - 01/2008
2	19,20-dihydroxydocosapentaenoic acidIBA 12/2019 - 01/2019
2	Acetyl-CoA CarboxylaseIBA 01/2019 - 04/2013
2	Pharmaceutical PreparationsIBA 01/2019 - 10/2009
2	ApolipoproteinsIBA 01/2019 - 11/2004
2	Adenosine Triphosphate (ATP)IBA 12/2018 - 07/2009
2	Sphingosine-1-Phosphate ReceptorsIBA 09/2017 - 05/2009
2	ProteomeIBA 01/2017 - 07/2012
2	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 09/2014 - 06/2014
2	LipopolysaccharidesIBA 06/2014 - 07/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2013 - 01/2008
2	Streptozocin (Streptozotocin)FDA Link 04/2013 - 09/2008
2	Phosphotransferases (Kinase)IBA 12/2011 - 01/2008
2	MonocrotalineIBA 03/2011 - 02/2009
2	TRPC6 Cation ChannelIBA 02/2011 - 12/2008
2	Apolipoproteins E (ApoE)IBA 05/2010 - 06/2007
2	AdiponectinIBA 07/2009 - 03/2009
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/2009 - 01/2006

Therapy/Procedure

6	Therapeutics 01/2020 - 01/2008
2	Ligation 01/2019 - 05/2010